William Blair Issues Optimistic Estimate for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Analysts at William Blair increased their FY2024 earnings per share (EPS) estimates for shares of Zoetis in a research report issued on Monday, November 4th. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of $5.89 for the year, up from their prior estimate of $5.83. The consensus estimate for Zoetis’ current full-year earnings is $5.91 per share. William Blair also issued estimates for Zoetis’ Q1 2025 earnings at $1.45 EPS, Q4 2025 earnings at $1.54 EPS, Q1 2026 earnings at $1.64 EPS, Q2 2026 earnings at $1.86 EPS and FY2026 earnings at $7.14 EPS.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 52.59%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the company posted $1.36 EPS.

ZTS has been the topic of several other reports. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus raised their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Price Performance

ZTS opened at $174.34 on Wednesday. The firm has a market cap of $78.98 billion, a PE ratio of 32.67, a P/E/G ratio of 2.68 and a beta of 0.90. The stock has a 50-day moving average price of $188.46 and a 200-day moving average price of $179.17. Zoetis has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.99%. Zoetis’s dividend payout ratio is 32.33%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Personal Financial Services bought a new position in shares of Zoetis during the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the third quarter valued at $33,000. Quarry LP lifted its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. LRI Investments LLC purchased a new position in shares of Zoetis in the 1st quarter worth $43,000. Finally, Fortitude Family Office LLC increased its holdings in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.